Clinical Trials Browser

Phase 1 × Recurrence × gilteritinib × Clear all

NCT05330377 2023-04-25

GM-CLAG in Relapsed/Refractory FLT3-mutated AML

Phase 1 Withdrawn

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT03625505 2021-09-14

A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Participants With Relapsed/Refractory Acute Myeloid Leukemia

Phase 1 Completed

Other hematologic neoplasm

Neoplasms, Recurrence, Leukemia, Myeloid, Acute